Keep current on the latest news from Allegro Ophthalmics

Sign up today to be notified about the initiation of clinical trials, study results and breaking company news.

Your info will never be shared with a third-party

No Thanks

Welcome to Allegro Ophthalmics

Accelerated Innovation. Needed Intervention.

With over 100 years of combined experience, the seasoned leadership team at Allegro Ophthalmics is dedicated to delivering and establishing Integrin Peptide Therapy TM as the next generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema. The potential to liberate patients from legal blindness to a much improved quality of life sustained by self-sufficient functional vision propels and accelerates our efforts.

Allegro Vision & Mission
Our vision is truly to ensure that more people keep their vision and do not suffer from blindness.


Allegro’s oligopeptide shows promise with a new mechanism of action for the prevention and management of ophthalmic disorders.